APSR2026-280

Yes
Late-Breaking
Submitted
Oral Presentation
AO06-005
 
 
https://storage.unitedwebnetwork.com/files/1285/1208742-46903-APSR2026-280 MASHKUR_440569.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Mashkur Muhamad * Hospital Sultanah Nur Zahirah Respiratory Unit, Department of Internal Medicine Kuala Terengganu Malaysia
Azlina Samsudin - Hospital Sultanah Nur Zahirah Respiratory Unit, Department of Internal Medicine Kuala Terengganu Malaysia
Nurul Majidah Abdul Razak - Hospital Sultanah Nur Zahirah Respiratory Unit, Department of Internal Medicine Kuala Terengganu Malaysia
Jamiatul Ezma Mohd Azili - Hospital Sultanah Nur Zahirah Respiratory Unit, Department of Internal Medicine Kuala Terengganu Malaysia
Che Ku Noor Haniza Che Ku Hitam - Hospital Sultanah Nur Zahirah Clinical Research Centre Unit Kuala Terengganu Malaysia
Anis Syafrina Mohamad Radhi - Hospital Sultanah Nur Zahirah Department of Internal Medicine Kuala Terengganu Malaysia
Mohamad Tarmizi Yahya - Hospital Sultanah Nur Zahirah Department of Internal Medicine Kuala Terengganu Malaysia
 
 
 
 
 
 
 
 
Presenting Author Details
Mashkur
Muhamad
mashkurmuhamad@yahoo.com
+60163384607
31-40
Malaysia
Original Research
Molecular testing in non-small cell lung carcinoma: Comparative insights from HSNZ Terengganu patients
Maximum 25 words
Abstract Content
Molecular testing enables targeted therapy in advanced non-small cell lung cancer (NSCLC) and may improve survival. Variations in laboratory pathways may affect treatment timeliness. This study evaluated the association between molecular testing, treatment modality, overall survival (OS), and time to treatment initiation by laboratory type at HSNZ.
A retrospective cohort study was conducted at HSNZ, including patients with advanced NSCLC diagnosed between January and December 2023. Demographic, clinical, molecular, treatment, and survival data were obtained from electronic medical records. OS was analysed using Kaplan–Meier curves and log-rank tests. Time to treatment initiation between patients with public and private laboratory results was compared using the Mann–Whitney U test. Statistical significance was set at p < 0.05.
Sixty-five patients with advanced NSCLC were analysed. The majority were male (72.7%), aged 61–70 years (34.8%), and adenocarcinoma accounted for 92.3% of cases. Molecular testing was performed in 61.5% of patients, predominantly through public laboratories (77.5%). During follow-up, 80.0% of patients died. Median OS for the entire cohort was 186 days (95% CI 104.7–267.3). Survival differed significantly by treatment modality (log-rank χ² = 28.75, p < 0.001). Patients receiving oral tyrosine kinase inhibitors (TKIs) had the longest OS (median 621 days, 95% CI 608.7–633.3), while median OS was not reached in the chemotherapy group. Patients managed with supportive care had significantly poorer survival (median 105 days, 95% CI 43.7–166.3). No significant difference in waiting time to treatment initiation was observed between public and private laboratories for chemotherapy (p = 0.511) or TKI therapy (p = 1.000).
Molecular testing facilitates access to targeted therapy and is associated with improved survival in advanced NSCLC. Laboratory type did not significantly affect treatment initiation time. Expanding equitable molecular testing access remains essential to improve lung cancer outcomes in Malaysia.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Non-small cell lung cancer, Molecular testing, Overall survival
maximum 3 keywords and no abbreviations, separated by commas
The authors declare no conflicts of interest. No external funding was received for this study.
307